These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37352473)

  • 41. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
    Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
    Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
    Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.
    Meyer RE; Salzman C; Youngstrom EA; Clayton PJ; Goodwin FK; Mann JJ; Alphs LD; Broich K; Goodman WK; Greden JF; Meltzer HY; Normand SL; Posner K; Shaffer D; Oquendo MA; Stanley B; Trivedi MH; Turecki G; Beasley CM; Beautrais AL; Bridge JA; Brown GK; Revicki DA; Ryan ND; Sheehan DV
    J Clin Psychiatry; 2010 Aug; 71(8):e1-e21. PubMed ID: 20797373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of treatment outcomes in psychiatry--where do we stand ?
    McMahon FJ
    Dialogues Clin Neurosci; 2014 Dec; 16(4):455-64. PubMed ID: 25733951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Perfusion magnetic resonance imaging in psychiatry.
    Théberge J
    Top Magn Reson Imaging; 2008 Apr; 19(2):111-30. PubMed ID: 19363433
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Psychoradiological Biomarkers for Psychopharmaceutical Effects.
    Schrantee A; Ruhé HG; Reneman L
    Neuroimaging Clin N Am; 2020 Feb; 30(1):53-63. PubMed ID: 31759572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of the Status and Future Direction for Digital Therapeutics in Children and Adolescent Psychiatry.
    Choi H; Kim B; Kim I; Kang JG; Lee Y; Lee H; Park MH
    Soa Chongsonyon Chongsin Uihak; 2023 Oct; 34(4):192-203. PubMed ID: 37841489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Role of Biomarkers in Psychiatry.
    Lozupone M; La Montagna M; D'Urso F; Daniele A; Greco A; Seripa D; Logroscino G; Bellomo A; Panza F
    Adv Exp Med Biol; 2019; 1118():135-162. PubMed ID: 30747421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Precision psychiatry in clinical practice.
    Zanardi R; Prestifilippo D; Fabbri C; Colombo C; Maron E; Serretti A
    Int J Psychiatry Clin Pract; 2021 Mar; 25(1):19-27. PubMed ID: 32852246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Valley of death: A proposal to build a "translational bridge" for the next generation.
    Gamo NJ; Birknow MR; Sullivan D; Kondo MA; Horiuchi Y; Sakurai T; Slusher BS; Sawa A
    Neurosci Res; 2017 Feb; 115():1-4. PubMed ID: 27876581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1.
    Sinniah RS; Shapses MS; Ahmed MU; Babiker H; Chandana SR
    Expert Opin Investig Drugs; 2021 Oct; 30(10):1047-1056. PubMed ID: 34579607
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology.
    Grabb MC; Gobburu JVS
    Prog Neurobiol; 2017 May; 152():38-57. PubMed ID: 27216638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Precision Psychiatry: Machine Learning as a Tool to Find New Pharmacological Targets.
    Rema J; Novais F; Telles-Correia D
    Curr Top Med Chem; 2022; 22(15):1261-1269. PubMed ID: 34607546
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Future viable models of psychiatry drug discovery in pharma.
    Rizzo SJ; Edgerton JR; Hughes ZA; Brandon NJ
    J Biomol Screen; 2013 Jun; 18(5):509-21. PubMed ID: 23392517
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Personalized Medicine and Mood Disorders.
    Alhajji L; Nemeroff CB
    Psychiatr Clin North Am; 2015 Sep; 38(3):395-403. PubMed ID: 26300030
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Letter to the Editor: Depression As The First Symptom Of Frontal Lobe Grade 2 Malignant Glioma.
    Nazlı ŞB; Sevindik M
    Turk Psikiyatri Derg; 2022; 33(2):143-145. PubMed ID: 35730515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Artificial Intelligence Effecting a Paradigm Shift in Drug Development.
    Rashid MBMA
    SLAS Technol; 2021 Feb; 26(1):3-15. PubMed ID: 32940124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Applications of artificial intelligence to new drug development].
    Moingeon P
    Ann Pharm Fr; 2021 Sep; 79(5):566-571. PubMed ID: 33529579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biomarkers of psychiatric diseases: current status and future prospects.
    Kalia M; Costa E Silva J
    Metabolism; 2015 Mar; 64(3 Suppl 1):S11-5. PubMed ID: 25467847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.